DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2knv66/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Alnylam Pharmaceuticals, Inc.
- Amarna Therapeutics B.V.
- Apitope International NV
- AstraZeneca Plc
- Bayer AG
- Biogen, Inc.
- BioMarin Pharmaceutical Inc.
- Catalyst Biosciences, Inc.
- Celtic Pharmaceutical Holdings L.P.
- CSL Limited
- DBV Technologies S.A.
- Dimension Therapeutics, Inc.
- Dong-A Socio Group
- Emergent BioSolutions Inc.
- EpiVax, Inc.
- Expression Therapeutics LLC
- F. Hoffmann-La Roche Ltd.
- Green Cross Corporation
- Inbiopro Solutions Pvt. Ltd.
- Lentigen Technology, Inc.
- Novo Nordisk A/S
- Octapharma AG
- OPKO Health, Inc.
- Pharming Group N.V.
- Promethera Biosciences S.A.
- rEVO Biologics
- Sangamo BioSciences, Inc.
- Selecta Biosciences, Inc.
- SK Chemicals Co., Ltd.
- Spark Therapeutics, Inc.
- The International Biotechnology Center (IBC) Generium
- uniQure N.V.
For more information visit http://www.researchandmarkets.com/research/2knv66/hemophilia_a
